Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases

December 11, 2020
Lisa Astor

Sacituzumab govitecan led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial.

Sacituzumab govitecan (Trodelvy) led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC) who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial. There was no improvement in overall survival (OS) for this population, however, with sacituzumab govitecan compared to standard chemotherapy.1

“Although the sample size was small, in this exploratory analysis of very poor prognosis patients with brain metastases in ASCENT, [sacituzumab govitecan] provided numerically better responses rates and PFS, but not overall survival relative to chemotherapy,” Véronique Diéras, MD, of the Centre Eugéne-Marquis in Rennes, France, said in a poster presentation during the 2020 San Antonio Breast Cancer Symposium.

Sacituzimab govitecan is a novel antibody-drug conjugate (ADC) consisting of an anti–Trop-2 monoclonal antibody conjugated to SN-38 and a hydrolyzable linker. SN-38 is used in central nervous system regimens as it can cross the blood-brain barrier, Diéras explained.

The phase 3 ASCENT trial (NCT02574455) enrolled 529 patients with mTNBC who had received at least 2 chemotherapy regimens for advanced disease. These patients were randomized 1:1 to either receive sacituzumab govitecan at 10 mg/kg intravenously on days 1 and 8 of every 3-week cycle of treatment of physician’s choice. Treatment was continued until progression or unacceptable toxicity.

Results presented at the European Society for Medical Oncology Congress 2020 showed that the median PFS with sacituzumab govitecan was 5.6 months compared with 1.7 months with chemotherapy (HR, 0.41; P < .0001) and the median OS was 12.1 versus 6.7 months, respectively (HR, 0.48; P < .0001). The ORR was 35% with sacituzumab govitecan and 5% with physician’s choice of treatment.2

The subgroup analysis focused on 61 patients in the trial who had stable brain metastases for at least 4 weeks by MRI, although 2 in the sacituzumab govitecan group and 6 in the chemotherapy group were not treated. Of the 32 patients in the ADC arm with brain metastases, 6% remain on treatment as of data cutoff versus none in the control arm. The primary reason for discontinuation was disease progression.1

These patients had a median age of 53 years (range, 27-80) in the investigational arm and 51 years (range, 34-81) in the control arm. A majority of patients in both arms were White, had an ECOG performance status of 1, and were negative for BRCA1/2 mutations. The median number of prior regimens was 5 (range, 2-10), and a total of 43% had received prior checkpoint inhibition.

ORR in the brain metastasis population was 3% with sacituzumab govitecan versus 0% with chemotherapy, and the disease control rates were 9% and 3%, respectively. Rates of stable diseases were 47% and 31% in the ADC and chemotherapy arms, respectively, but only 2 patients in the sacituzumab govitecan group and 1 in the chemotherapy group had stable disease lasting for more than 6 months.

The median PFS was 2.8 months (95% CI, 1.5-3.9) with sacituzumab govitecan and 1.6 months (95% CI, 1.3-2.9) with chemotherapy (HR, 0.65; 95% CI, 0.35-1.22). At 3 months, the PFS rate was 41.4% with the ADC and 27.7% with chemotherapy. By 9 months the corresponding PFS rates were 9.0% and 0%.

Median OS was 6.8 months (95% CI, 4.7-14.1) with sacituzumab govitecan and 7.5 months (95% CI, 4.7-11.1) with physician’s choice of treatment (HR, 0.87; 95% CI, 0.47-1.63).

The safety profile was similar to that of the overall ASCENT population, Diéras said. The most common treatment-emergent adverse events for sacituzumab govitecan versus chemotherapy were fatigue (63% vs 52%, respectively), neutropenia/decreased neutrophil count (63% vs 52%), diarrhea (50% vs 13%), and nausea (43% vs 26%). No treatment-related deaths were reported in either treatment arm.

The ADC was granted an accelerated approval by the FDA in April 2020 for the treatment of adult patients with mTNBC who have received at least 2 prior therapies in the metastatic setting based on results from the IMMU-132-01 trial (NCT01631552).

References:

1. Diéras V, Weaver R, Tolaney SM, et al. Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD13-04.

2. Bardia A, Tolaney SM, Loirat D, et al. ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31(suppl 4):S1149-S1150. doi:10.1016/j.annonc.2020.08.2245